Skip to main content
Top
Published in: Pediatric Nephrology 11/2007

01-11-2007 | Brief Report

Protracted remission of proteinuria after combined therapy with plasmapheresis and anti-CD20 antibodies/cyclophosphamide in a child with oligoclonal IgM and glomerulosclerosis

Authors: Gian Marco Ghiggeri, Luca Musante, Giovanni Candiano, Maurizio Bruschi, Laura Santucci, Giancarlo Barbano, Antonella Trivelli, Lucia Rivabella, Rosanna Gusmano, Francesco Perfumo

Published in: Pediatric Nephrology | Issue 11/2007

Login to get access

Abstract

We describe a child presenting with oligoclonal plasma IgM (1.2 g%) and nephrotic syndrome with focal segmental glomerulosclerosis. Oligoclonality was demonstrated by the analysis of the complementary determining region 3 (CDR 3) on immunoglobulin heavy chains and by two dimensional electrophoresis and Western blot analysis that showed the bulk of isoforms having a cationic μU chain compared with the normal homologue (pI 7.5 vs 6.5). Urinary light chains were absent, and bone marrow aspirate was normal. Usual therapies for nephrotic syndrome with steroids and cyclosporin were useless. At the age of 9 years the patient was treated with plasmapheresis plus cyclophosphamide (2 mg/kg per day for 60 days), which temporarily reduced plasma IgM, and proteinuria was normal for 3 years. After this period, due to new recurrence of nephrotic syndrome, the patient received a cycle with anti-CD20 antibodies (500 mg/m2 every week for a month) associated with a cycle of plasmapheresis that normalized proteinuria again, and, after 3 years, the proteinuria is still in remission. This is the first case of nephrotic syndrome associated with oligoclonal plasma IgM and mesangial IgM deposits. Both cyclophosphamide and anti-CD20 antibodies associated with plasmapheresis induced, at different stages, stable and protracted remission of proteinuria without evident side effects. Long term efficacy and safety of the association are still to be determined.
Literature
1.
go back to reference Cohen AH, Border WA, Glassock RJ (1978) Nephrotic syndrome with glomerular mesangial IgM deposits. Lab Invest 38:610–619PubMed Cohen AH, Border WA, Glassock RJ (1978) Nephrotic syndrome with glomerular mesangial IgM deposits. Lab Invest 38:610–619PubMed
2.
go back to reference Border WA (1988) Distinguishing minimal-change disease from mesangial disorders. Kidney Int 34:419–434CrossRef Border WA (1988) Distinguishing minimal-change disease from mesangial disorders. Kidney Int 34:419–434CrossRef
3.
go back to reference Gonzalo A, Mampaso F, Gallego N, Quereda C, Fierro C, Ortuno J (1985) Clinical significance of IgM mesangial deposits in the nephrotic syndrome. Nephron 41:246–249CrossRef Gonzalo A, Mampaso F, Gallego N, Quereda C, Fierro C, Ortuno J (1985) Clinical significance of IgM mesangial deposits in the nephrotic syndrome. Nephron 41:246–249CrossRef
4.
go back to reference McAdams AJ, Valentini RP, Welch TR (1997) The nonspecificity of focal segmental glomerulosclerosis. The defining characteristics of primary focal glomerulosclerosis, mesangial proliferation, and minimal change. Medicine (Baltimore) 76:42–52CrossRef McAdams AJ, Valentini RP, Welch TR (1997) The nonspecificity of focal segmental glomerulosclerosis. The defining characteristics of primary focal glomerulosclerosis, mesangial proliferation, and minimal change. Medicine (Baltimore) 76:42–52CrossRef
5.
go back to reference Korbet SM (1998) Primary focal segmental glomerulosclerosis. J Am Soc Nephrol 9:1333–1340PubMed Korbet SM (1998) Primary focal segmental glomerulosclerosis. J Am Soc Nephrol 9:1333–1340PubMed
6.
go back to reference International Study of Kidney Disease in Children (1974) Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children. Lancet 2:423–427 International Study of Kidney Disease in Children (1974) Prospective, controlled trial of cyclophosphamide therapy in children with nephrotic syndrome. Report of the International study of Kidney Disease in Children. Lancet 2:423–427
7.
go back to reference International Study of Kidney Disease in Children (1981) Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children. Kidney Int 20:765–771CrossRef International Study of Kidney Disease in Children (1981) Primary nephrotic syndrome in children: clinical significance of histopathologic variants of minimal change and of diffuse mesangial hypercellularity. A Report of the International Study of Kidney Disease in Children. Kidney Int 20:765–771CrossRef
8.
go back to reference Au WY, Chan KW, Lui SL, Lam CC, Kwong YL (1999) Focal segmental glomerulosclerosis and mesangial sclerosis associated with myeloproliferative disorders. Am J Kidney Dis 34:889–893CrossRef Au WY, Chan KW, Lui SL, Lam CC, Kwong YL (1999) Focal segmental glomerulosclerosis and mesangial sclerosis associated with myeloproliferative disorders. Am J Kidney Dis 34:889–893CrossRef
9.
go back to reference Bosly A, Keating MJ, Stasi R, Bradstock K (2002) Rituximab in B-cell disorders other than non-Hodgkin’s lymphoma. Anticancer Drugs 13 [Suppl 2]:S25–S33CrossRef Bosly A, Keating MJ, Stasi R, Bradstock K (2002) Rituximab in B-cell disorders other than non-Hodgkin’s lymphoma. Anticancer Drugs 13 [Suppl 2]:S25–S33CrossRef
10.
go back to reference Benz K, Dotsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19:794–797CrossRef Benz K, Dotsch J, Rascher W, Stachel D (2004) Change of the course of steroid-dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol 19:794–797CrossRef
11.
go back to reference Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M (2005) Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 20:1660–1663CrossRef Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M (2005) Rituximab treatment for posttransplant lymphoproliferative disorder (PTLD) induces complete remission of recurrent nephrotic syndrome. Pediatr Nephrol 20:1660–1663CrossRef
12.
go back to reference Francois H, Daugas E, Bensman A, Ronco P (2007) Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am J Kidney Dis 49:158–161CrossRef Francois H, Daugas E, Bensman A, Ronco P (2007) Unexpected efficacy of rituximab in multirelapsing minimal change nephrotic syndrome in the adult: first case report and pathophysiological considerations. Am J Kidney Dis 49:158–161CrossRef
13.
go back to reference Pescovitz MD, Book BK, Sidner RA (2006) Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 354:1961–1963CrossRef Pescovitz MD, Book BK, Sidner RA (2006) Resolution of recurrent focal segmental glomerulosclerosis proteinuria after rituximab treatment. N Engl J Med 354:1961–1963CrossRef
14.
go back to reference Marks SD, McGraw M (2007) Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation? Pediatr Nephrol 22:158–160CrossRef Marks SD, McGraw M (2007) Does rituximab treat recurrent focal segmental glomerulosclerosis post-renal transplantation? Pediatr Nephrol 22:158–160CrossRef
15.
go back to reference Cunard R, Kelly CJ (2002) T cells and minimal change disease. J Am Soc Nephrol 13:1409–1411CrossRef Cunard R, Kelly CJ (2002) T cells and minimal change disease. J Am Soc Nephrol 13:1409–1411CrossRef
16.
go back to reference Rennke HG, Venkatachalam MA (1979) Glomerular permeability of macromolecules. Effect of molecular configuration on the fractional clearance of uncharged dextran and neutral horseradish peroxidase in the rat. J Clin Invest 63:713–717CrossRef Rennke HG, Venkatachalam MA (1979) Glomerular permeability of macromolecules. Effect of molecular configuration on the fractional clearance of uncharged dextran and neutral horseradish peroxidase in the rat. J Clin Invest 63:713–717CrossRef
17.
go back to reference Clyne DH, Pesce AJ, Thompson RE (1979) Nephrotoxicity of Bence Jones proteins in the rat: importance of protein isoelectric point. Kidney Int 16:345–352CrossRef Clyne DH, Pesce AJ, Thompson RE (1979) Nephrotoxicity of Bence Jones proteins in the rat: importance of protein isoelectric point. Kidney Int 16:345–352CrossRef
18.
go back to reference Smolens P, Barnes JL, Stein JH (1986) Effect of chronic administration of different Bence Jones proteins on rat kidney. Kidney Int 30:874–882CrossRef Smolens P, Barnes JL, Stein JH (1986) Effect of chronic administration of different Bence Jones proteins on rat kidney. Kidney Int 30:874–882CrossRef
Metadata
Title
Protracted remission of proteinuria after combined therapy with plasmapheresis and anti-CD20 antibodies/cyclophosphamide in a child with oligoclonal IgM and glomerulosclerosis
Authors
Gian Marco Ghiggeri
Luca Musante
Giovanni Candiano
Maurizio Bruschi
Laura Santucci
Giancarlo Barbano
Antonella Trivelli
Lucia Rivabella
Rosanna Gusmano
Francesco Perfumo
Publication date
01-11-2007
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 11/2007
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-007-0550-y

Other articles of this Issue 11/2007

Pediatric Nephrology 11/2007 Go to the issue